Potential conflicts of interest: K. Chayama has received research grants and consulting fees from Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma, Daiichi Sankyo, Toray Industries, Otsuka Pharmaceutical Co., and GlaxoSmithKline KK. N. Izumi has received lecture fees from Chugai and MSD, and Bristol-Myers KK. K. Yamamoto has received research funding from Chugai, MSD, and Bristol-Myers KK. T. Takehara has received research grants and lecture fees from Bristol-Myers Squibb. K. Koike is on the speakers' bureau for Bristol-Myers Squibb. Hidetaka Miyagoshi, Timothy Eley, Fiona McPhee, Andrew Damokosh, Hiroki Ishikawa, and Eric Hughes are employees of Bristol-Myers Squibb or Bristol-Myers KK. Drs. Eley and McPhee also own stock in Bristol-Myers Squibb. All other authors have no conflicts to report.
Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection
Version of Record online: 1 APR 2014
Copyright © 2014 The Authors. HEPATOLOGY published by Wiley on behalf of the American Association for the Study of Liver Diseases.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Volume 59, Issue 6, pages 2083–2091, June 2014
How to Cite
Kumada, H., Suzuki, Y., Ikeda, K., Toyota, J., Karino, Y., Chayama, K., Kawakami, Y., Ido, A., Yamamoto, K., Takaguchi, K., Izumi, N., Koike, K., Takehara, T., Kawada, N., Sata, M., Miyagoshi, H., Eley, T., McPhee, F., Damokosh, A., Ishikawa, H. and Hughes, E. (2014), Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology, 59: 2083–2091. doi: 10.1002/hep.27113
This study was funded by Bristol-Myers Squibb.
- Issue online: 28 MAY 2014
- Version of Record online: 1 APR 2014
- Accepted manuscript online: 6 MAR 2014 06:10AM EST
- Manuscript Accepted: 28 FEB 2014
- Manuscript Received: 10 FEB 2014
- 10Coadministration of BMS-790052 and BMS-650032 does not result in a clinically meaningful pharmacokinetic interaction in healthy subjects [abstract]. Hepatology 2010;52(Suppl):719A., , , , , , et al.
- 13Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012;55:742–748., , , , , , et al.
- 19Gilead Sciences. Gilead announces SVR12 rates from three phase 3 studies evaluating a once-daily fixed-dose combination of sofosbuvir and ledipasvir for genotype 1 hepatitis C patients. December 18, 2013. http://www.gilead.com/news/press-releases/2013/12/gilead-announces-svr12-rates-from-three-phase-3-studies-evaluating-a-oncedaily-fixeddose-combination-of-sofosbuvir-and-ledipasvir-for-genotype-1-hepatitis-c-patients.
- 20Abbvie, Inc. AbbVie completes largest phase III program of an all-oral, interferon-free therapy for the treatment of hepatitis C genotype 1. January 31, 2014. http://abbvie.mediaroom.com/2014-01-31-AbbVie-Completes-Largest-Phase-III-Program-of-an-All-Oral-Interferon-Free-Therapy-for-the-Treatment-of-Hepatitis-C-Genotype-1.